170 related articles for article (PubMed ID: 23814489)
1. Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor cells to rapamycin.
Ricci-Vitiani L; Runci D; D'Alessandris QG; Cenci T; Martini M; Bianchi F; Maira G; Stancato L; De Maria R; Larocca LM; Pallini R
Neoplasia; 2013 Jul; 15(7):773-82. PubMed ID: 23814489
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a Clival Chordoma Xenograft Model Reveals Tumor Genomic Instability.
Diaz RJ; Luck A; Bondoc A; Golbourn B; Picard D; Remke M; Loukides J; Sabha N; Smith C; Cusimano MD; Rutka JT
Am J Pathol; 2018 Dec; 188(12):2902-2911. PubMed ID: 30248342
[TBL] [Abstract][Full Text] [Related]
3. Brachyury gene copy number gain and activation of the PI3K/Akt pathway: association with upregulation of oncogenic Brachyury expression in skull base chordoma.
Otani R; Mukasa A; Shin M; Omata M; Takayanagi S; Tanaka S; Ueki K; Saito N
J Neurosurg; 2018 May; 128(5):1428-1437. PubMed ID: 28753115
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
5. A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology.
Trucco MM; Awad O; Wilky BA; Goldstein SD; Huang R; Walker RL; Shah P; Katuri V; Gul N; Zhu YJ; McCarthy EF; Paz-Priel I; Meltzer PS; Austin CP; Xia M; Loeb DM
PLoS One; 2013; 8(11):e79950. PubMed ID: 24223206
[TBL] [Abstract][Full Text] [Related]
6. T gene isoform expression pattern is significantly different between chordomas and notochords.
Wang K; Hu Q; Wang L; Chen W; Tian K; Cao C; Wu Z; Jia G; Zhang L; Zeng C; Zhang J
Biochem Biophys Res Commun; 2015 Nov; 467(2):261-7. PubMed ID: 26435504
[TBL] [Abstract][Full Text] [Related]
7. Response to imatinib plus sirolimus in advanced chordoma.
Stacchiotti S; Marrari A; Tamborini E; Palassini E; Virdis E; Messina A; Crippa F; Morosi C; Gronchi A; Pilotti S; Casali PG
Ann Oncol; 2009 Nov; 20(11):1886-94. PubMed ID: 19570961
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
Gulhati P; Zaytseva YY; Valentino JD; Stevens PD; Kim JT; Sasazuki T; Shirasawa S; Lee EY; Weiss HL; Dong J; Gao T; Evers BM
Carcinogenesis; 2012 Sep; 33(9):1782-90. PubMed ID: 22696593
[TBL] [Abstract][Full Text] [Related]
9. Higher cMET dependence of sacral compared to clival chordoma cells: contributing to a better understanding of cMET in chordoma.
Lohberger B; Scheipl S; Heitzer E; Quehenberger F; de Jong D; Szuhai K; Liegl-Atzwanger B; Rinner B
Sci Rep; 2021 Jun; 11(1):12466. PubMed ID: 34127734
[TBL] [Abstract][Full Text] [Related]
10. Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis.
Kitamura Y; Sasaki H; Kimura T; Miwa T; Takahashi S; Kawase T; Yoshida K
J Neuropathol Exp Neurol; 2013 Sep; 72(9):816-23. PubMed ID: 23965741
[TBL] [Abstract][Full Text] [Related]
11. Durable complete response to chemotherapy in an infant with a clival chordoma.
Al-Rahawan MM; Siebert JD; Mitchell CS; Smith SD
Pediatr Blood Cancer; 2012 Aug; 59(2):323-5. PubMed ID: 21922644
[TBL] [Abstract][Full Text] [Related]
12. Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer.
Bradshaw-Pierce EL; Pitts TM; Kulikowski G; Selby H; Merz AL; Gustafson DL; Serkova NJ; Eckhardt SG; Weekes CD
PLoS One; 2013; 8(3):e58089. PubMed ID: 23520486
[TBL] [Abstract][Full Text] [Related]
13. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Histone H3K27 Demethylases Inactivates Brachyury (TBXT) and Promotes Chordoma Cell Death.
Cottone L; Cribbs AP; Khandelwal G; Wells G; Ligammari L; Philpott M; Tumber A; Lombard P; Hookway ES; Szommer T; Johansson C; Brennan PE; Pillay N; Jenner RG; Oppermann U; Flanagan AM
Cancer Res; 2020 Oct; 80(20):4540-4551. PubMed ID: 32855205
[TBL] [Abstract][Full Text] [Related]
15. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM
J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079
[TBL] [Abstract][Full Text] [Related]
16. Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas.
Han S; Polizzano C; Nielsen GP; Hornicek FJ; Rosenberg AE; Ramesh V
Clin Cancer Res; 2009 Mar; 15(6):1940-6. PubMed ID: 19276265
[TBL] [Abstract][Full Text] [Related]
17. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
Ducker GS; Atreya CE; Simko JP; Hom YK; Matli MR; Benes CH; Hann B; Nakakura EK; Bergsland EK; Donner DB; Settleman J; Shokat KM; Warren RS
Oncogene; 2014 Mar; 33(12):1590-600. PubMed ID: 23542178
[TBL] [Abstract][Full Text] [Related]
18. K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.
Wei F; Liu Y; Bellail AC; Olson JJ; Sun SY; Lu G; Ding L; Yuan C; Wang G; Hao C
Cancer Lett; 2012 Sep; 322(1):58-69. PubMed ID: 22342683
[TBL] [Abstract][Full Text] [Related]
19. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
20. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
Shao W; Mishina YM; Feng Y; Caponigro G; Cooke VG; Rivera S; Wang Y; Shen F; Korn JM; Mathews Griner LA; Nishiguchi G; Rico A; Tellew J; Haling JR; Aversa R; Polyakov V; Zang R; Hekmat-Nejad M; Amiri P; Singh M; Keen N; Dillon MP; Lees E; Ramurthy S; Sellers WR; Stuart DD
Cancer Res; 2018 Mar; 78(6):1537-1548. PubMed ID: 29343524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
